Abstract
Introduction
Rheumatoid arthritis (RA) often involves an altered T-cell subpopulation, higher levels of inflammatory cytokines, and auto-antibodies. This study investigated whether PDCD5 could be a biomarker to predict the incidence and remission of RA so as to guide the therapeutic management of clinical RA.
Methods
One hundred fifty-two patients (41 being in both active status and stable remission status) who were newly diagnosed with RA and 38 healthy controls were enrolled. Basic clinical data were collected before using blood samples remaining in the clinic after routine complete blood count. The ability of PDCD5 and important indicators to predict the remission of RA was estimated based on receiver operating characteristic curve (ROC) analysis.
Results
PDCD5 expression was found to be significantly increased in RA patients in active status in comparison with healthy controls or those in stable remission status. Compared with anti-CCP, ESR and DAS28 score, PDCD5 was of better predictive value with an AUC of 0.846 (95% CI 0.780–0.912) for RA remission. The incidence risk of RA increased with higher levels of PDCD5 (OR = 1.73, 95% CI = 1.45–1.98, P = 0.005) in multiple logistic regression analysis, with the risk increasing by 2.94-times for high-risk group in comparison with low-risk group (OR = 2.94, 95% CI = 2.35–4.62, P < 0.001). The association between PDCD5 and RA remission showed a similar result. For correlation analysis, significant associations were eventually found between PDCD5 and indicated genes (FOXP3, TNF-α, IL-17A, IFN-γ and IL-6) as well as several important clinical parameters including IgG, RF, CRP, ESR, anti-CCP and DAS28 score.
Conclusions
This study suggested that increased PDCD5 expression was significantly linked to the incidence and remission of RA. PDCD5 may be used as a novel biomarker for the prediction of RA incidence and remission, especially due to its potential involvement in the development of the condition.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
As an inflammatory autoimmune disease, rheumatoid arthritis (RA) often involves an altered T-cell subpopulation as well as higher levels of inflammatory cytokines and auto-antibodies. The current authors previously reported that PDCD5 could inhibit RA by regulating those T cells and inflammatory cytokines. |
The aim of this study is to investigate whether PDCD5 could be a biomarker to predict the incidence and remission of RA so as to guide the therapeutic management of clinical RA. |
What was learned from the study? |
This study suggested that increased PDCD5 expression was significantly linked to the incidence and remission of RA. |
PDCD5 may be used as a novel biomarker for the prediction of RA incidence and remission, especially due to its potential involvement in the development of the condition. |
Introduction
It is now an established fact that rheumatoid arthritis (RA) is a chronic disease, mediated by a malfunctioning immune system, whereby effector T cells and inflammatory pathways trigger an impaired tissue repair process. The latter subsequently damages different organs, especially in the joints, although the vascular system and the lungs may also be affected [1]. In this context, biomarkers can be very helpful in managing and treating the different phases of RA. Indeed, they allow disease development to be predicted in high-risk patients, while improving diagnosis by closing the serological gap. Furthermore, biomarkers help to monitor disease activity and progression, thereby providing information that is of prognostic value in deciding on treatment options as well as in assessing treatment responses and outcomes [2].
The apoptosis-related gene programmed cell death 5 (PDCD5) had been cloned in 1999 from TF-1 cells undergoing apoptosis [3]. It has already been shown that this gene could interact with Tip60 to enhance its stability and promote the acetylation of FOXP3. This subsequently caused naïve T cells to differentiate into Treg cells, thereby enhancing the latter’s immunosuppressive functions on effector T cells [4]. In fact, based on a rat model of collagen-induced arthritis, PDCD5 could even protect against RA by regulating the balance between Treg cells and effector T cells such as Th1 and Th17 [5]. Further studies have also indicated that, through the activation induced cell death (AICD) of auto-reactive T cells, PDCD5 inhibited the secretion of inflammatory cytokines [6, 7]. Therefore, it has been established that PDCD5 is an immune regulation-related gene.
PDCD5 is up-regulated in different inflammation- and autoimmune-related diseases. For instance, in autoimmune diseases of the central nervous system, increased expression of PDCD5 and FOXP3 was noted in the blood of multiple sclerosis (MS) patients in comparison with healthy controls [8]. Similarly, significant up-regulation of PDCD5 has been reported in viral infections [9], inflammation-activated peripheral blood mononuclear cells (PBMCs), as well as inflammatory fibrotic lung tissues [10, 11]. As far as RA patients are concerned, serum and synovial levels of the PDCD5 protein were also significantly higher in comparison with healthy controls [12, 13]. However, studies that correlate levels of PDCD5 expression with RA progression are still missing. Hence, the current work compares the level of PDCD5 expression in blood samples during the acute and stable phase of RA patients and investigates the gene’s ability to predict the incidence and remission of RA before eventually evaluating the correlation between PDCD5 expression and cytokine levels. Based on the results, it can be inferred that PDCD5 could represent a new biomarker with a better efficacy at predicting the incidence and remission of RA.
Methods
Study Population
Newly diagnosed RA patients (152 patients), based on the American College of Rheumatology criteria [14], who were admitted to Xiangyang Central Hospital between August 2022 and March 2023 were included in the study. Of these, information from a sample of 41 patients was collected during both the active and stable remission status. For this study, clinically active was defined as any sign of systemic disease or any joint showing active disease, while stable remission was defined as the absence of signs and symptoms of significant inflammatory disease activity which had lasted for more than three consecutive months [15].
The exclusion criteria applied for the RA patients were as follows: (1) being diagnosed with other autoimmune diseases; (2) a history of chronic diseases; (3) treatment with any immunosuppressive drugs and/or glucocorticoid within 1 month; (4) missing information about age, gender, and important clinical laboratory tests.
Thirty-eight healthy individuals were also enrolled as healthy controls (HC) from the Physical Examination Center of the hospital where they had undergone physical tests. The age and gender distribution of this group generally matched those of the RA patients.
The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study protocol was approved by the Ethics Committee of Hubei University of Arts and Science (No. 2022-030). Informed written consent was obtained from all subject participants in the study. The authors are accountable for all aspects of the work, including ensuring that any questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Measurement of Clinical Indicators
For the RA patients, basic clinical data, including various biochemical indices such as rheumatoid factor (RF), C-reactive protein (CRP), white blood cells (WBC), lymphocytes (LYMPH), lymphocyte% (LYM%), neutrophil% (NEU%), anti-cyclic citrullinated peptide (CCP), hemoglobin (HGB), hematocrit (HCT), immunoglobulin (Ig) A, IgM, IgG and erythrocyte sedimentation rate (ESR) were obtained. IMMAGE800 (Beckman Coulter) was used to measure IgA, IgM, IgG and RF, while i-CHROMA (BodiTech) allowed CRP to be determined. Similarly, a Vacuette ESR System (Greiner Bio-One) provided measurements of ESR, while Sysmex XE-2100 (TOA Medical) enabled the detection of lymphocytes and WBC. Eventually, anti-CCP was detected with Sprinter XL (Euroimmun) using the indirect immunofluorescence test. The Disease Activity Score in 28 joints (DAS28 score) was estimated to assess the degree of disease activity, as previously reported [16].
RNA Extraction and qPCR
Blood samples which remained in the clinic after routine complete blood count (CBC) were collected for RNA extraction. Two milliliters of whole blood in ethylenediaminetetraacetic acid vacutainer was first centrifuged (3000 rpm, 7 min, 4 °C) to remove the plasma, with the resulting pellet subsequently suspended in 2 ml of red cell lysing reagent (A11895, Beckman Coulter) for 5 min. This was followed by centrifugation (3000 rpm, 5 min, 4 °C) to remove the lysis buffer, and after washing two times with 2 ml of PBS (2000 rpm, 5 min, 4 °C), the pellet was resuspended in 1 ml of TRIzol (269212, Ambion) prior to storage at – 80 °C. RNA was eventually extracted before undertaking qPCR as described before [5, 17].
For PCR, the following specific primer sequences were used: Human PDCD5: (F) 5’-CTTGAGGCGCTGAGGAGAC-3’, (R) 5’-GGCCGACTGATCCAGAACTT-3’; Human FOXP3: (F) 5’-TCTTCCTTGAACCCCATGCC-3’, (R) 5’-AAATGTGGCCTGTCCTGGAG-3’; Human INF-γ: (F) 5’-TCCAGTTACTGCCGGTTTGA-3’, (R) 5’-TGGAAGCACCAGGCATGAAA-3’; Human IL-17A: (F) 5’-TAATGGCCCTGAGGAATGGC-3’, (R) 5’-AGGAAGCCTGAGTCTAGGGG-3’; Human IL-6: (F) 5’-GTCCAGTTGCCTTCTCCCTG-3’, (R) 5’-CTGAGATGCCGTCGAGGATG-3’; Human TNF-α: (F) 5’-GACAGATGTGGGGTGTGAGAA-3’, (R) 5’-TCTGTGTGCCAGACACCCTA-3’; Human GAPDH: (F) 5’- GACCACAGTCCATGCCATCAC-3’ and (R) 5’-TCCACCACCCTGTTGCTGTAG-3’. qPCR assays and an ABI 7500 instrument were utilized to collect the data. The expression levels of PDCD5 as well as other genes were calculated using the 2 × 2−ΔΔCt method, with the normalization according to housekeeping genes (GAPDH).
Statistical Analysis
To highlight the characteristics of continuous data, means ± SD (standard deviations) were determined, with N (percentage) subsequently provided in the case of qualitative ones. In addition, differences in variables were qualitatively and quantitatively analyzed using chi-square test and Student’s t test, respectively, while differences between the means of more than two groups were evaluated with one-way ANOVA. The association between PDCD5 expression and the level of different biochemical indices was also assessed based on linear correlation analysis. Moreover, the ability of PDCD5 as well as other important indicators to predict the remission of RA was determined using receiver operating characteristic curve (ROC) analysis. Finally, univariate and multiple logistic regression provided the multivariable adjusted odds ratio (OR) for the relationship between PDCD5 expression and incidence and remission of RA, along with the 95% confidence interval (CI). In this case, age, gender, smoking status, and drinking status as well as diseases history were included as the model’s covariates. For all analyses, two-sided P values < 0.05 were indicative of statistically significant differences. For statistical analysis and the graphics, SAS 9.4 software (SAS Institute) and GraphPad Prism 5 software were used, respectively.
Results
Demographic and Clinical Features of Participants
For the current study, 152 RA patients (58 patients were selected in stable remission status) and 38 healthy controls were enrolled, with their characteristics shown in Table 1. Overall, the RA patients (including 58 patients in stable remission status) and healthy controls were not significantly different in terms of age (59.20 ± 14.00 vs. 56.43 ± 9.72, P = 0.204) and gender (female: 71.1 vs. 63.2%, P = 0.129). Similar results were also noted when comparing smoking and drinking status between the two groups. However, compared with the healthy controls, a significantly higher count of WBC (7.98 ± 3.97 vs. 6.04 ± 1.25, P = 0.021) and LYMPH (4.41 ± 0.58 vs. 2.05 ± 0.73, P = 0.032) but a significantly lower level of HCT (33.71 ± 6.15 vs. 37.25 ± 5.29, P = 0.042) were noted for RA patients.
Higher PDCD5 Expression in RA Patients
Differences in PDCD5 expression were evaluated based on qPCR (Fig. 1). As shown in Fig. 1A, PDCD5 expression of healthy controls was compared with that of RA patients. In this case, it was observed that, for RA patients, mRNA levels of PDCD5 were significantly higher compared with the controls (0.76 ± 0.07 vs. 0.24 ± 0.052, P < 0.001). In addition, the information of 41 RA patients were collected during both active and stable remission status. Results showed a significant decrease in the PDCD5 expression of RA patients achieving stable remission in comparison with those in the active status (0.59 ± 0.07 vs. 1.01 ± 0.13, P = 0.003; Fig. 1B).
High Expression Level of PDCD5 was Significantly Linked to the Incidence and Remission of RA
Univariate and multiple logistic regression were used to determine the link between PDCD5 expression and the incidence and remission of RA (Table 2). After accounting for age, gender, smoking and drinking status as well as diseases history, the incidence risk of RA increased with higher expression of PDCD5 (OR = 1.73, 95% CI = 1.45–1.98, P = 0.005). Based on the median level (0.52) of PDCD5 mRNA expression, participants were subsequently assigned to low- or high-risk groups, with the incidence risk of RA increasing by 2.94-fold for the latter group (OR = 2.94, 95% CI = 2.35–4.62, P < 0.001). A similar result was also shown when analyzing the association between PDCD5 expression and remission of RA patients. Multiple logistic regression analysis showed that when compared with the low-risk group (median value = 2.08), people in the high-risk group had a 4.06-fold decreased probability of remission (OR = 4.06, 95% CI = 2.80–5.94, P < 0.001).
The Predictive Ability of PDCD5 was Better Than Important Clinical Indicators for the Remission of RA
The ability of PDCD5 and important clinical indicators to predict the remission of RA was estimated using ROC analysis (Fig. 2). Compared with ESR, anti-CCP, and the DAS28 score, PDCD5 was of better predictive value for the remission of RA, with an AUC of 0.846 (95% CI 0.780–0.912) as well as a specificity and sensitivity of 88.1 and 86.6%, respectively. AUCs of 0.779 (95% CI 0.692–0.866) for ESR, 0.817 (95% CI 0.749–0.885) for anti-CCP and 0.813 (95% CI 0.745–0.881) for the DAS28 score were also obtained for RA prediction. These results indicated that the predictive ability of PDCD5 was better than several important clinical indicators for the remission of RA and therefore PDCD5 could potentially be used as a novel biomarker.
Positive Correlation Between PDCD5 Expression and Several Important Clinical Parameters in RA Patients
For RA patients, correlations between PDCD5 expression and clinical parameters such as DAS28 score, anti-CCP, IgM, IgA, IgG, RF, CRP, and ESR, were analyzed to explore the significance of the higher gene expression in RA. As shown in Fig. 3, PDCD5 expression was positively and significantly correlated with the levels of ESR (r = 0.772, P < 0.001), CRP (r = 0.755, P < 0.001), RF (r = 0.767, P < 0.001), anti-CCP (r = 0.656, P < 0.001) and DAS28 score (r = 0.707, P < 0.001). Furthermore, PDCD5 expression was significantly correlated with IgG (r = 0.744, P < 0.001), IgA (r = 0.714, P < 0.001) and IgM (r = 0.648, P < 0.001).
In addition, differences in PDCD5 expression at high and low levels of important RA clinical indicators were also conducted in this study (Fig. 4). After dividing the RA patients into a high and a low group based on the median value of RF, a significantly higher level of PDCD5 expression was observed for the high-risk group (1.35 ± 0.26 vs. 0.60 ± 0.21, P = 0.006). This difference was actually more obvious in the case of ESR, anti-CCP and the DAS28 score (1.36 ± 0.14 vs. 0.51 ± 0.11, P < 0.001; 1.17 ± 0.13 vs. 0.56 ± 0.07, P < 0.001; 1.05 ± 0.12 vs. 0.69 ± 0.09, P = 0.022; respectively).
Association Between PDCD5 and Cytokines in RA Patients
FOXP3, TNF-α, IL-17A, IL-6, and IFN-γ are important for the remission and relapse phases of RA [18, 19] and, as previously reported, PDCD5 up-regulated FOXP3 and cytokines in rat models of RA [5]. To estimate the role of these factors in the increased expression of PDCD5 in RA patients, the expression levels of FOXP3, TNF-α, IL-17A, IL-6, and IFN-γ were determined. As shown in Fig. 1C–F, the blood sample of RA patients displayed a significant increase in the expression levels of FOXP3, TNF-α, IFN-γ, and IL-17A in comparison with the healthy controls (0.11 ± 0.02 vs. 0.02 ± 0.01, P < 0.001 for FOXP3; 0.23 ± 0.03 vs. 0.02 ± 0.01, P < 0.001 for TNF-α; 0.40 ± 0.04 vs. 0.09 ± 0.02, P < 0.001 for IFN-γ and 0.10 ± 0.01 vs. 0.01 ± 0.00, P < 0.001 for IL-17A).
To evaluate the association between PDCD5 expression and cytokines in all RA patients, especially those in the active status, linear correlation analysis was performed. Correlation analyses conducted for all RA patients (Fig. 5) indicated a positive relationship between PDCD5 expression and IL-17A (r = 0.722, P < 0.001), IFN-γ (r = 0.717, P < 0.001), TNF-α (r = 0.715, P < 0.001), IL-6 (r = 0.672, P < 0.001) as well as FOXP3 (r = 0.680, P < 0.001). In addition, correlation analysis was also undertaken specifically for active RA patients, with significant associations again found between PDCD5 expression and the cytokines. These findings not only indicated that the cytokines were related to PDCD5 expression in RA patients but also suggested that the gene could potentially regulate the pathologic microenvironment of RA.
Discussion
The current study revealed a significant increase in PDCD5 expression for RA patients in the active status in comparison with those in stable remission as well as healthy controls. In addition, according to the results of ROC analysis, PDCD5 was better than several important clinical indicators, such as RF, anti-CCP, and the DAS28 score, at predicting the remission of RA. Multiple logistic regression analysis further indicated that high levels of PDCD5 expression increased the incidence and decreased the remission probability of RA, which was 2.94 and 4.06 times higher for high-risk groups compared with low-risk groups. Furthermore, for correlation analysis, a significant association was found between PDCD5 expression and cytokines as well as several important clinical parameters, hence suggesting that, in RA patients, the cytokine levels in the plasma were related to PDCD5 expression. Overall, this study suggests that PDCD5 could represent a novel biomarker for predicting the incidence and remission of RA, with the results indicating that the gene could be important for the development of RA.
Early painful and swollen joints as well as subsequent extra-articular manifestations are the main characteristics of RA, an inflammatory autoimmune disease [20]. Therefore, diagnosing the condition at an early stage and providing aggressive treatment can be important in view of reducing disease activity while improving the long-term prognosis [21]. Several biomarkers and clinical parameters have been reported as being linked with the incidence and remission of RA [22,23,24]. For instance, a miRNA (miR-99b-5p) was found to suppress T cell apoptosis, promote cell proliferation and activation, and improve the expression of proinflammatory cytokines [22]. One study reported that MYD88 was associated with clinical severity status of RA patients and showed a higher level in active status than stable remission status [23]. A comprehensive analysis of laboratory parameters at admission was performed to identify remission of RA patients [25,26,27]. Large unstained anti-CCP, RA, IgM, and DAS28 scores proved to be key laboratory predictors of RA remission [26]. In particular, it has been reported that several clinical predictors, such as ESR, RF, anti-CCP and DAS28 score, showed low discrimination ability for identifying RA patients at an early stage [27]. As a result, the prediction efficiency of these markers, either laboratory parameters or genetic epigenetic biomarkers, is not satisfactory. In this study, mRNA expression levels of PDCD5 showed a satisfactory prediction efficacy for the early identification of disease incidence and remission for RA patients, with the predictive value being better than that of other predictors reported in several studies.
It has already been shown that PDCD5 could interact directly with FOXP3 to enhance the latter’s repressive function [4]. In this study, it was found that both PDCD5 and FOXP3 were up-regulated in active RA in comparison with healthy controls or stable RA. Furthermore, PDCD5 expression was significantly correlated with that of FOXP3 in all the RA and active RA patients, thereby indicating that PDCD5 could be involved in inducing FOXP3 expression in RA. Since PDCD5 and FOXP3 are immuno-modulators that largely exert anti-inflammatory and immunosuppressive functions in RA [5, 28], it may seem surprising that active RA was characterized by higher expression levels of their genes. However, the broad spectrum of action of these molecules could justify the above findings.
PDCD5 exerts complex biological functions such as promoting apoptosis as a result of various stimuli or inhibiting immune inflammation via TIP60-FOXP3-Treg axis [29]. Furthermore, abnormal expression of this gene is involved in different inflammatory autoimmune diseases [29]. In a similar way to the current results, significantly higher levels of the PDCD5 protein have been reported in RA patients in comparison with healthy controls [12]. In particular, PDCD5 gene expression is significantly increased during autoimmune diseases such as MS, in HIV-infected individuals, or in monocytes activated by inflammatory stimuli [8].
In RA patients, FOXP3 levels increase significantly, with a positive correlation also noted with RA activity score and disease grade. The results suggest that, in RA patients, FOXP3 may not by a reliable indicator of Treg-mediated immune regulation [30], although in MS, its expression is significantly increased [8]. Recently activated conventional human T cells also display high expression of FOXP3 which is an important determinant of Treg development and function [31, 32]. Unlike Tregs where FOXP3 is more stably expressed, in vitro activation of conventional human T cells displays transient upregulation of FOXP3 without acquiring suppressive capabilities. However, the above observation may also be noted in vivo, especially in individuals with ongoing immune responses where T cells are chronically stimulated [33]. This would explain why the current cohort of patients had higher FOXP3 levels.
Activation-induced cell death (AICD) of effector T cells is a protective mechanism used by the host immune system for counteracting the abnormal survival of autoreactive lymphocytes [34]. PDCD5 promotes AICD of auto-reactive inflammatory Th1 and Th17 cells which can secrete TNF-α, IFN-γ, IL-17A, and IL-6 [5,6,7]. Therefore, the current findings indicate that increased PDCD5 expression in RA could represent a defense mechanism that seeks to eliminate auto-reactive immune cells that have developed an “apoptosis-resistant” feature. Higher expression of PDCD5 may even reflect enhanced apoptotic processes in RA patients, as this would explain the positive correlation between increased PDCD5 expression in RA and the cytokines (TNF-α, IFN-γ, IL-17A, and IL-6).
This is the first study that examines the importance of PDCD5 expression in predicting the incidence and remission of RA patients. Based on a large population and disease types in both active and stable remission status, the significant relationship between PDCD5 expression and the incidence as well as remission of RA was reported for the first time. PDCD5 showed good efficacy for the prediction of disease status and clinical outcomes. However, the study was not without certain limitations. The cell counts/percentages of WBC, LYMPH, and HCT differ between RA and healthy controls. Probably, subpopulations of whole white cells may affect the expression levels of each gene. We only measured gene expression in whole white cells in this study. Therefore, a breakdown by cell type to verify if the differences in PDCD5 expression were due to differences in cell counts or specific cell populations was quite important and necessary. Actually, we further examined PDCD5 expression in PBMCs and granulocytes, and it was found that the expression trend of PDCD5 in PMBCs and granulocytes was consistent with that in the whole blood. There were no significant differences in PDCD5 expression in the whole blood, granulocytes, and PBMCs. Therefore, it was observed that the conclusion reached in this study could be considered scientific and representative. Further studies, including PDCD5 expression in specific cell populations in large RA samples, should be conducted in the future.
Conclusions
In conclusion, the current work highlights how high levels of PDCD5 were significantly linked to the incidence and remission of RA. Hence, the gene could potentially regulate the pathologic microenvironment of RA. PDCD5 may also be useful as a novel biomarker for the prediction of RA incidence and remission due to its potential involved in the development of RA.
References
Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–8.
Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Biomarkers in rheumatoid arthritis. Isr Med Assoc J. 2017;19(8):512–6.
Liu H, Wang Y, Zhang Y, Song Q, Di C, Chen G, Tang J, Ma D. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun. 1999;254(1):203–10.
Xiao J, Liu C, Li G, Peng S, Hu J, Qu L, Lv P, Zhang Y, Ma D, Chen Y. PDCD5 negatively regulates autoimmunity by upregulating FOXP3(+) regulatory T cells and suppressing Th17 and Th1 responses. J Autoimmun. 2013;47:34–44.
Xiao J, Li G, Hu J, Qu L, Ma D, Chen Y. Anti-inflammatory effects of recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced model of arthritis. Inflammation. 2015;38(1):70–8.
Xiao J, Liu W, Chen Y, Deng W. Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis. J Neuroinflammation. 2015;12(1):117.
Wanlin W, Chun M, Juan X. rhPDCD5 suppresses pro-inflammatory cytokine secretion and proliferation and induces apoptosis of activated lymphocytes from rats with collagen-induced arthritis. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(6):627–32.
Perga S, Martire S, Montarolo F, Giordani I, Spadaro M, Bono G, Corvisieri S, Messuti I, Panzica G, Orlandi F, et al. The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto’s Thyroiditis. Front Immunol. 2018;9:311.
Motomura K, Toyoda N, Oishi K, Sato H, Nagai S, Hashimoto S, Tugume SB, Enzama R, Mugewa R, Mutuluuza CK, et al. Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals. Int Immunopharmacol. 2004;4(14):1829–36.
Haudek-Prinz VJ, Klepeisz P, Slany A, Griss J, Meshcheryakova A, Paulitschke V, Mitulovic G, Stockl J, Gerner C. Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells. J Proteom. 2012;76(5):150–62.
Park SY, Hong JY, Lee SY, Lee SH, Kim MJ, Kim SY, Kim KW, Shim HS, Park MS, Lee CG, et al. Club cell-specific role of programmed cell death 5 in pulmonary fibrosis. Nat Commun. 2021;12(1):2923.
Wang JF, Guan ZP, Zhang SL, Pei Z, Chen YY, Pan H. Programmed cell death 5 correlates with disease activity and interleukin-17 in serum and synovial fluid of rheumatoid arthritis patients. Chin Med J (Engl). 2013;126(2):296–9.
Wang J, Guan Z, Ge Z. Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-alpha and disease activity in patients with rheumatoid arthritis. Biomarkers. 2013;18(2):155–9.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
Vander CB, Van LS, Wyns B, Westhovens R, Durez P, Van d BF, et al. Das28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the das28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063–71.
Xiao J, Shen X, Kou R, Wang K, Zhai L, Ding L, Chen H, Mao C. Kirenol inhibits inflammation challenged by lipopolysaccharide through the AMPK-mTOR-ULK1 autophagy pathway. Int Immunopharmacol. 2023;116: 109734.
Jiang H, Xu F, Zeng L, Li C, Chen Y, Wang L, Li Z, Liu R. Saponins from Nigella glandulifera seeds attenuate collagen-induced rheumatoid arthritis in rats via the OPG/RANKL/NF-kappaB and Ang/Tie-2 pathways. J Ethnopharmacol. 2022;283: 114714.
Zeng L, Li C, Jiang H, Chen Y, Li Z, Xu F, Liu R. Total Saponins from Nigella glandulifera Seeds Ameliorate Adjuvant-Induced Rheumatoid Arthritis in Rats by Inhibition of an Inflammatory Response and Bone Erosion. Biomed Res Int. 2021;2021:6613527.
Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
Zhu X, Wu L, Mo X, Xia W, Guo Y, Wang M, et al. Identification of PBMC-expressed miRNAs for rheumatoid arthritis. Epigenetics. 2020;15(4):386–97.
Gomes SI, Lima CAD, Silva JEA, Rushansky E, Mariano MHQA, Rolim P, et al. Is there an inflammation role for MYD88 in rheumatoid arthritis? Inflammation. 2021;44(3):1014–22.
He X, Liu J, Liang C, Badshah SA, Zheng K, Dang L, et al. Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis. EBioMedicine. 2019;41:538–55.
Huang YJ, Chen JS, Luo SF, Kuo CF. Comparison of indexes to measure comorbidity burden and predict all-cause mortality in rheumatoid arthritis. J Clin Med. 2021;10(22):5460.
Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, Ito H, Matsuda S. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35–44.
Xue L, Tao L, Li X, Wang Y, Wang B, Zhang Y, et al. Plasma fibrinogen, D-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11(1):16903.
Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and role of regulatory T cells in rheumatoid arthritis. Front Immunol. 2021;12: 626193.
Li G, Ma D, Chen Y. Cellular functions of programmed cell death 5. Biochim Biophys Acta. 2016;1863(4):572–80.
Ikram EM, Allam AA, Meawed TE, Abd El-Wahab SM, Ramadan RA. Forkhead Box P3 (FOXP3) serum level and FOXP3 gene-promoter polymorphisms in Egyptian rheumatoid arthritis patients: A case-control study. Egypt J Immunol. 2021;28(2):53–64.
Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006;103(17):6659–64.
Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129–38.
Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med. 2004;199(9):1285–91.
Tang X, Yocum DE, Dejonghe D, Nordensson K, Lake DF, Richard J. Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action. Immunology. 2004;112(3):496–505.
Acknowledgements
The authors would like to thank all the reviewers who participated in the study.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contribution
Juan Xiao, Ke Wang, and Anbing Zhang designed research; Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, and Hong Xiao conducted research; Ke Wang, Lu Zhang, and Huabo Chen analyzed data; and Juan Xiao and Ke Wang wrote the paper. Juan Xiao, Ke Wang, and Anbing Zhang had primary responsibility for the final content. All authors read and approved the final manuscript.
Funding
This work was supported by the Key R&D Program of Hubei province (No. 2022BCE014), the Hubei Provincial Natural Science Foundation of China (No. 2022CFC032), Xiangyang Medical-health Areas Science and Technology Program (No. 2022YL03A) and the Research Foundation for Teacher Cultivation of Hubei University of Arts and Science (No. 2022pygpzk10). Anbing Zhang funded the journal’s Rapid Service Fee.
Medical writing/editorial assistance
The authors would like to thank MJEditor (www.mjeditor.com) for medical writing support during the preparation of this manuscript, which was funded by Anbing Zhang.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethical Approval
The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study protocol was approved by the Ethics Committee of Hubei University of Arts and Science (No. 2022-030). Informed written consent was obtained from all subject participants in the study. The authors are accountable for all aspects of the work, including ensuring that any questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.
Conflict of Interest
Juan Xiao, Fengqiao Zhou, Zhenwang Zhao, Fengsheng Cao, Hong Xiao, Lu Zhang, Huabo Chen, Ke Wang and Anbing Zhang have nothing to disclose.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Xiao, J., Zhou, F., Zhao, Z. et al. PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis. Rheumatol Ther 10, 1369–1383 (2023). https://doi.org/10.1007/s40744-023-00587-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-023-00587-5